Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes

References

• Global Initiative for Asthma. Available from: Global Strategy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed January 2, 2020.
   Google Scholar
• Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012;42(5):650–658. doi:10.1111/j.1365-2222.2011.03929.x
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37–42. doi:10.1016/j.anai.2015.10.027
   PubMed Web of Science ®Google Scholar
• Bonser LR, Erle DJ. The airway epithelium in asthma. Adv Immunol. 2019;142:1–34.
   PubMed Web of Science ®Google Scholar
• Genentech. Omalizumab (XOLAIR) US prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103976s5231lbl.pdf. Accessed January 2, 2020.
   Google Scholar
• Genentech. Omalizumab (XOLAIR) EU summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf. Accessed January 2, 2020.
   Google Scholar
• GlaxoSmithKline. Mepolizumab (NUCALA) US prescribing information. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF. Accessed January 2, 2020.
   Google Scholar
• GlaxoSmithKline. Mepolizumab (NUCALA) EU summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf. Accessed January 2, 2020.
   Google Scholar
• Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68(2):158–166. doi:10.1016/j.alit.2019.01.004
   PubMedGoogle Scholar
• Albers FC, Mullerova H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152–160. doi:10.1080/02770903.2017.1322611
   PubMed Web of Science ®Google Scholar
• Tabatabaian F, Ledford DK. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy. 2018;11:53–61. doi:10.2147/JAA.S107982
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Pelaia G, et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020;50(7):780–788. doi:10.1111/cea.13613
   PubMed Web of Science ®Google Scholar
• Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26(5):812–818. doi:10.1183/09031936.05.00037905
   Web of Science ®Google Scholar
• O’Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax. 2015;70(4):376–378. doi:10.1136/thoraxjnl-2013-204114
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Dalal AA, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016;4(1):120–129. doi:10.1016/j.jaip.2015.08.003
   PubMed Web of Science ®Google Scholar
• Mullerova H, Cockle SM, Gunsoy NB, Nelsen LM, Albers FC. Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL Study. J Asthma. 2019;1–16.
   Web of Science ®Google Scholar
• Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726. doi:10.1111/all.13850
   PubMed Web of Science ®Google Scholar
• Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140(6):1509–1518. doi:10.1016/j.jaci.2017.10.005
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. doi:10.1016/S2213-2600(16)30031-5
   PubMed Web of Science ®Google Scholar
• Ramsahai JM, Hansbro PM, Wark PAB. Mechanisms and Management of Asthma Exacerbations. Am J Respir Crit Care Med. 2019;199(4):423–432. doi:10.1164/rccm.201810-1931CI
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. doi:10.1038/nri3786
   PubMed Web of Science ®Google Scholar
• Arroyave WD, Rabito FA, Carlson JC. The relationship between a specific IgE level and asthma outcomes: results from the 2005–2006 National Health and Nutrition Examination Survey. J Allergy Clin Immunol Pract. 2013;1(5):501–508. doi:10.1016/j.jaip.2013.06.013
   PubMed Web of Science ®Google Scholar
• Calderon MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48. doi:10.1016/j.jaci.2014.10.012
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):1715–1725. doi:10.1001/jama.2016.3964
   PubMed Web of Science ®Google Scholar
• Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013;132(6):1322–1336. doi:10.1016/j.jaci.2013.09.004
   PubMed Web of Science ®Google Scholar
• Shafique RH, Klimov PB, Inam M, Chaudhary FR, OConnor BM. Group 1 allergen genes in two species of house dust mites, Dermatophagoides farinae and D. pteronyssinus (Acari: pyroglyphidae): direct sequencing, characterization And polymorphism. PLoS One. 2014;9(12):e114636. doi:10.1371/journal.pone.0114636
   Web of Science ®Google Scholar
• Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J. 2014;44(1):239–241. doi:10.1183/09031936.00220413
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–1492. doi:10.1016/j.rmed.2007.01.011
   PubMed Web of Science ®Google Scholar
• Harris JM, Wong DA, Kapp AV. Development of the Asthma Control Composite outcome measure to predict omalizumab response. Ann Allergy Asthma Immunol. 2011;107(3):273–280. doi:10.1016/j.anai.2011.06.005
   Web of Science ®Google Scholar